Tools for Practice Outils pour la pratique


#299 Cardiovascular prevention trials: Now calling colchicine to the stand


CLINICAL QUESTION
QUESTION CLINIQUE
Is colchicine effective for secondary cardiovascular prevention?


BOTTOM LINE
RÉSULTAT FINAL
Daily low-dose colchicine in people with coronary artery disease (CAD) lowers the risk of cardiovascular events by ~1%/year (relative risk reduction 25-30%), but increases the risk of gastrointestinal events (mostly diarrhea) by ~2% and has no effect on mortality.



CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session



EVIDENCE
DONNÉES PROBANTES
  • At least 7 systematic reviews compared the effect of colchicine to placebo in addition to standard therapy in individuals with CAD [4-11 randomized controlled trials (RCTs), 5820-12869 participants, duration 5 days to 3 years].1-7
    • All showed similar:
      • Colchicine reduced cardiovascular events [relative risk reduction (RRR) ~30%].
      • No difference in mortality.
    • Most meta-analyses evaluating gastrointestinal events found ~2% absolute risk with colchicine (mostly diarrhea).2,3,6
  • Two largest placebo-controlled, good quality RCTs, non-industry funded:
    • LoDoCo2 trial8 compared colchicine 0.5mg daily versus placebo for 2.5 years in 5522 participants (age≈66, 15% female) with stable CAD.
      • Cardiovascular events (cardiovascular mortality, myocardial infarction, ischemic strokes, urgent revascularization): Colchicine 6.8% versus 9.6% placebo, RRR=29%, number needed to treat (NNT)=36.
      • No significant difference in mortality (2.6% versus 2.2%).
      • No difference in adverse events except myalgias (NNH=38).
    • COLCOT trial9 compared colchicine 0.5mg daily versus placebo for 23 months in 4745 participants (age≈61, 19% female) within 1 month after myocardial infarction.
      • Cardiovascular events (cardiovascular mortality, myocardial infarction, strokes, urgent revascularization): Colchicine 5.5% versus 7.1% placebo, RRR=24%, NNT=63.
      • No difference in mortality (1.8% in both groups).
      • No difference in any or serious adverse events.
  • Limitations: Excluded individuals with various risk factors for colchicine toxicity (examples kidney or muscular disease) and one trialhad an open-label colchicine run-in period that excluded 15% of patients before randomization, mostly because of adverse events.
Context
  • Recent guidelines for secondary prevention in CAD or post-myocardial infarction do not make any recommendations about colchicine.10,11
  • The new 0.5mg dose costs ~$45 for a 3-month supply (versus $25 for 0.6mg dose).12,13
  • Colchicine efficacy on cardiovascular events better [example ezetimibe (RRR ~6%)] or comparable [example aspirin or statins (RRR~25%)] to other preventive therapies, but without the benefits on mortality of aspirin and statins.14,15 


oluw adebajo October 12, 2021

nice article

paul duchastel October 15, 2021

A very old drug rehabilitated

Michel Cauchon October 22, 2021

balance between benefits and risks


Latest Tools for Practice
Derniers outils pour la pratique

#363 Making a difference in indifference? Medications for apathy in dementia

In patients with dementia, how safe and effective are stimulants, antidepressants, and antipsychotics for treating apathy?
Read Lire 0.25 credits available Crédits disponibles

#362 Facing the Evidence in Acne, Part I: Oral contraceptives and spironolactone in females

How effective are combined oral contraceptives (COC) and spironolactone for treating acne of at least mild-moderate severity in females?
Read Lire 0.25 credits available Crédits disponibles

#361 Preventing RSV Infections in Infants

How safe and effective are monoclonal antibodies to prevent respiratory syncytial virus (RSV) infections in infants?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session


Author(s)
Auteur(s)
  • Nicolas Dugré PharmD MSc BCPAC
  • Stéphane Vanier MD CCFP
  • Ricky D Turgeon BSc (Pharm) ACPR PharmD

1. Xia M, Yang X, Qian C. Am J Cardio. 2021; 140:33-38.

2. Ullah W, Gowda SN, Fischman D. Cardiovasc Revasc Med. 2021; 23:1-6.

3. Xiang Z, Yang J, Yang J, et al. Intern Emerg Med. 2021; 16(2):487-496.

4. Samuel M, Tardif JC, Bouabdallaoui N, et al. Can J Cardiol. 2021; 37(5):776-785.

5. Fiolet AT, Opstal TS, Mosterd A, et al. Eur Heart J. 2021; ehab115.

6. Andreis A, Imazio M, Piroli F, et al. Eur J Prev Cardiol. 2021; zwab045.

7. Al-Abdouh A, Barbarawi M, Khan SU, et al. Coron Artery Dis. 2020 Jul 23. doi:10.1097/MCA.0000000000000931. Online ahead of print.

8. Nidorf SM, Fiolet AT, Mosterd A, et al. N Engl J Med. 2020; 383:1838-1847.

9. Tardif JC, Kouz S, Waters DD, et al. N Engl J Med. 2019; 381:2497-2505.

10. Knuuti J, Wijns W, Saraste A, et al. Eur Heart J. 2020; 41:407-77.

11. Collet JP, Thiele H, Barbato E, et al. Eur Heart J. 2021; 42:1289-367.

12. Interactive Drug Benefit List [website]. Edmonton, AB: Government of Alberta; 2021. Available from: https://idbl.ab.bluecross.ca/idbl/load.do. Accessed 2021 July 08.

13. PharmaClik. McKesson Canada. 2021. https://clients.mckesson.ca/ Accessed September 27, 2021.

14. Koskinas KC, Siontis GC, Piccolo R, et al. Eur Heart J. 2018; 39(14):1172-80.

15. Antithrombotic Trialists' Collaboration. BMJ. 2002; 324(7329):71.

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.